Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBITDA (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBITDA for 17 consecutive years, with $799000.0 as the latest value for Q1 2026.

  • Quarterly EBITDA rose 117.69% to $799000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Jan 2026, down 49.43% year-over-year, with the annual reading at $17.3 million for FY2026, 47.81% down from the prior year.
  • EBITDA for Q1 2026 was $799000.0 at Usana Health Sciences, up from -$6.5 million in the prior quarter.
  • The five-year high for EBITDA was $34.7 million in Q1 2022, with the low at -$6.5 million in Q3 2025.
  • Average EBITDA over 5 years is $12.0 million, with a median of $10.5 million recorded in 2022.
  • The sharpest move saw EBITDA soared 118.86% in 2023, then crashed 137.1% in 2025.
  • Over 5 years, EBITDA stood at $20.0 million in 2022, then rose by 16.43% to $23.3 million in 2023, then tumbled by 119.39% to -$4.5 million in 2024, then tumbled by 43.06% to -$6.5 million in 2025, then surged by 112.36% to $799000.0 in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at $799000.0, -$6.5 million, and $13.1 million for Q1 2026, Q3 2025, and Q2 2025 respectively.